Table 3.

Avipoxvirus vector based vaccines and prime-boost immunization regimes in clinical development for human use

Recombinant viral vector	Targeted pathogen/disease	Inserts	Vaccine details	Developer/Sponsors	Clinical phase	References
ALVAC containing the gene encoding HIV-1 gp160, and protein gp120	HIV-1	gp160 and gp120	ALVAC-HIV vCP1521 prime and AIDSVAX-gp120 subtype B/E boost	U.S. Army Medical Research and Materiel Command	III	[141]
ALVAC-HIV (vCP1452) and LIPO-5+vCP1452	HIV-1	LIPO-5	ALVAC-HIV (vCP1452) LIPO-5	NIH	I/II	[142]
VACV and ALVAC or FWPV with or without combination therapy	Cancer	CEA (pancarcinoma)	TRICOM vectors co-express B7.1, ICAM1 and LFA3	NIH	I/II	[143]
FWPV (FP9)	Malaria	Circumsporozoite (CSP) protein	Attenuated FP9 and Circumsporozoite (CSP) protein	Gates Malaria Partnership	I	[144]

HIV-1, human immunodeficiency virus 1; ALVAC, attenuated canarypox virus; gp160, glycoprotein 160; gp120, glycoprotein 120; VACV, vaccinia virus; FWPV, fowlpox virus; CEA, carcinoembryonic antigen; TRICOM, triad of costimulatory molecules; ICAM1, intercellular adhesion molecule 1; LFA3, lymphocyte function-associated antigen 3; LIPO-5, Lipopeptide 5; CSP, circumsporozoite protein; FP9, attenuated fowlpox virus 9; NIH, US National Institutes of Health.